Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Martin-Touaux, E.
Right arrow Articles by Poenaru, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin-Touaux, E.
Right arrow Articles by Poenaru, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, 2002, Vol. 11, No. 14 1637-1645
© 2002 Oxford University Press

Muscle as a putative producer of acid {alpha}-glucosidase for glycogenosis type II gene therapy

E. Martin-Touaux1,*, J.P. Puech2, D. Château3,{dagger}, C. Emiliani4, E.J. Kremer5,{ddagger}, N. Raben6, B. Tancini4, A. Orlacchio4, A. Kahn1 and L. Poenaru1,2

1Département de Génétique, Développement et Pathologie Moléculaire, Institut Cochin, INSERM U567, Paris, France, 2Université Paris V, Paris, France, 3INSERM U153, Hopital de la Salpétrière, Paris, France, 4Dipartimento di Scienze Biochimiche e Biotecnologie Molecolar, University of Perugia, Italy, 5Généthon III, CNRS URA 1923, Evry, France and 6NIH, Bethesda, MD, USA

Received March 1, 2002; Accepted April 29, 2002

Glycogenosis type II (GSD II) is a lysosomal disorder affecting skeletal and cardiac muscle. In the infantile form of the disease, patients display cardiac impairment, which is fatal before 2 years of life. Patients with juvenile or adult forms can present diaphragm involvement leading to respiratory failure. The enzymatic defect in GSD II results from mutations in the acid {alpha}-glucosidase (GAA) gene, which encodes a 76 kDa protein involved in intralysosomal glycogen hydrolysis. We previously reported the use of an adenovirus vector expressing GAA (AdGAA) for the transduction of myoblasts and myotubes cultures from GSD II patients. Transduced cells secreted GAA in the medium, and GAA was internalized by receptor-mediated capture, allowing glycogen hydrolysis in untransduced cells. In this study, using a GSD II mouse model, we evaluated the feasibility of GSD II gene therapy using muscle as a secretary organ. Adenovirus vector encoding AdGAA was injected in the gastrocnemius of neonates. We detected a strong expression of GAA in the injected muscle, secretion into plasma, and uptake by peripheral skeletal muscle and the heart. Moreover, glycogen content was decreased in these tissues. Electron microscopy demonstrated the disappearance of destruction foci, normally present in untreated mice. We thus demonstrate for the first time that muscle can be considered as a safe and easily accessible organ for GSD II gene therapy.

* To whom correspondence should be addressed at: Département de Génétique, Développement et Pathologie Moléculaire, Institut Cochin, INSERM U567, 24 rue du faubourg Saint-Jacques, 75014 Paris, France. Tel: +33 1 44412401; Email: emt{at}cochin.inserm.fr

{dagger} Present address: INSERM U505, Institut des Cordeliers, Paris, France.

{ddagger} Present address: Institut de Génétique Moléculaire de Montpellier, CNRS UMR 5535, Montpellier, France.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 DevelopmentHome page
M. Rucker, T. J. Fraites Jr, S. L. Porvasnik, M. A. Lewis, I. Zolotukhin, D. A. Cloutier, and B. J. Byrne
Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease
Development, June 15, 2004; 131(12): 3007 - 3019.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.